---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-017175"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2021-08-17T23:59:59+00:00"
generated_at: "2026-06-29T09:34:17.301570+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aurinia licenses novel peptide AUR300 from Riptide for autoimmune/fibrotic diseases; $6M upfront

## Summary
- Global licensing/research pact with Riptide for peptide AUR300 targeting M2 macrophages via CD206 receptor.
- Aurinia pays $6M upfront; potential milestones and royalties on future sales of AUR300.
- AUR300 reduces M2 dysregulation and inflammatory cytokines, aiming to treat autoimmune and fibrotic diseases.
- Joint development committee formed; Riptide handles tech transfer and indication research activities.
- Deal expands Aurinia's pipeline beyond LUPKYNIS into fibrosis and other autoimmune conditions.

## SEC filing metadata
- accession: 0001628280-21-017175
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2021-08-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828021017175/0001628280-21-017175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828021017175/auph-20210817.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-017175
- JSON: https://secwatch.observer/filing/0001628280-21-017175.json
- Plain text: https://secwatch.observer/filing/0001628280-21-017175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.